Ipsen : and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership -Today at 07:50 am

Agreement gives Ipsen global1 rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis

...

Related Keywords

France ,Macao ,Macau General ,Macau ,Hong Kong ,Pascal Prigent ,Ipsen Euronext ,David Loew ,Terns Pharmaceuticals ,European Medicines Agency ,Euronext ,Nasdaq ,Drug Administration ,European Commission ,Primary Biliary Cholangitis ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Chief Executive Officer ,Markets ,